Cancer Active Immunotherapy

Immunoprophylaxis and Immunorestoration
Softcover Nachdruck of the original 1. Auflage 1976
ISBN: 978-3-642-81019-0
Verlag: Springer

Buch, Englisch, Band 55, 408 Seiten, Format (B × H): 156 mm x 244 mm, Gewicht: 674 g

Reihe: Recent Results in Cancer Research

I would like to thank all my co-workers who have collaborated with me, from 1963 until now, in biological and clinical research in the field of cancer active immunotherapy, of its immuno­ prevention and immunorestoration. They will often be quoted in this book. I am particularly grateful to those who have helped me to write it by reviewing some chapters: D. BELPOMME, J. F. DOR~, IRENE FLORENTIN, A. GOUTNER, I. J. Hm, R. HUCHET and MARIE-CHRISTINE SIMMLER. I also thank NICOLE VRIZ, MARIE-CLAUDE SCHNEIDER, FENELLARIsELEY and M. JUVET for their willing and efficient co-operation in the preperation of the manuscript. I am finally grateful to all authors of books or articles who authorized me to reproduce their figures or tables. Paris, April 1976 G. MAT~ Contents Chapter 1. Introduction and Definitions 1 Chapter 2. Biological Basis: Tumour Associated Antigens, the Immune Machinery and Its Behaviour Concerning Cancer Cells 5 2. 1. Tumour-Associated Antigens 5 2. 2. The Immune Machinery 19 2. 2. 1. Humoral Mediated Immunity and Cell Mediated Immunity 19 2. 2. 2. T- and B-Lymphocyte and Monocyte Differen­ tiation 22 2. 2. 3. T-Lymphocyte Functions 25 2. 2. 4. B-Lymphocyte Functions 30 2. 2. 5. Macrophage Functions 31 2. 2. 6. K-Cell Function 32 2. 3. The Immune Machinery and Cancer Cells 33 2. 3. 1. Mechanisms Involved in Tumour Cell Rejec­ tion 33 2. 3. 1. 1. In vivo Evidence for Tumour Immunity 33 2. 3. 1. 2.

Zielgruppe

Research

Autoren/Hrsg.

Mathe, G.

Inhaltsverzeichnis

1. Introduction and Definitions.- 2. Biological Basis: Tumour Associated Antigens, the Immune Machinery and Its Behaviour Concerning Cancer Cells.- 2.1. Tumour-Associated Antigens.- 2.2. The Immune Machinery.- 2.3. The Immune Machinery and Cancer Cells.- 3. Systemic Active Immunotherapy.- 3.1. Experimental.- 3.2. Clinical.- 4. Cancer Local Active Immunotherapy.- 4.1. Experimental.- 4.2. Clinical.- 5. Towards Immunoprophylaxis.- 5.1. Experimental.- 5.2. Clinical.- 6. Towards Immune Restoration.- 6.1. Immunodeficiency Associated with Cancer, and Cancer Risk in Immunodeficiency Subjects.- 6.2. Attempts at Immunorestoration.- 7. Developmental Pharmacology.- 7.1. Systemic Specific Active Immunotherapy or Immunoprophylaxis.- 7.2. Systemic Non-Specific Active Immunointervention.- 7.3. Local Immunotherapy.- 8. Toxicology and Adverse Effects.- 8.1. Systemic Active Immunotherapy.- 8.2. Local Active Immunotherapy.- 9. Mechanisms of Favourable and Adverse Effects and of Failures.- 9.1. Systemic Immuno-Intervention.- 9.2. Local Immunotherapy.- 10. Conclusion: Immunotherapy and Immunorestoration Today in the Strategy of Cancer Treatment; Their Perspectives and that of Immunoprophylaxis.- 10.1. Evaluation of the Immune Status of the Patient.- 10.2. Attempts at Immunorestoration in Case of Immunodepression.- 10.3. The Patient is an Immunoresponder (Without or After Immunorestoration).- 10.4. Immunoprophylaxis of Cancer.- 11. Appendix: Towards Monitoring the Immunological Status and Its Modification Induced by Immunotherapy, Immunorestoration or Immunoprophylaxis.- 11.1. Exploration of General Responses.- 11.2. Attempts at Evaluating Responses to Tumour-Associated Antigens.